Loading
A phase 2 trial of Azenosertib in ovarian cancer, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, now recruiting.
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer is a phase 2 interventional study registered as NCT05128825 by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, with 310 participants planned, started 2022-02-17 and due to reach its primary completion in 2026-12-01. Interventions recorded: azenosertib. Conditions listed: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Azenosertib, High-grade serous ovarian cancer, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares Azenosertib, Ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/